AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

K Yen, J Travins, F Wang, MD David, E Artin, K Straley… - Cancer discovery, 2017 - AACR
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2 …

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

K Yen, J Travins, F Wang, MD David, E Artin… - Cancer …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Somatic gain-of-function mutations in isocitrate
dehydrogenases (IDH) 1 and 2 are found in multiple hematologic and solid tumors, leading …

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

K Yen, J Travins, F Wang, MD David, E Artin… - Cancer …, 2017 - europepmc.org
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2 …

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

K Yen, J Travins, F Wang, MD David… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2 …